ChemBio Annouces the Collaboration with FIND Moving to Development of HCV Point-Of-Care Diagnostic-Test
Shots:
- ChemBio will be using its patented DPP® technology platform to test rapid HCV core antigen assay
- Parallely- FIND is conducting pilot studies in six countries to introduce novel algorithms and demonstrate the impact of HCV rapid diagnostics
- FIND plans to assess the outcomes of the feasibility studies in Dec’18 and fund one company for further development and validation of the HCV core antigen assay
- As per WHO- ~71Mn people are suffering from HCV infection with nearly 400-00 deaths/yr
Ref: Chembio Diagnostics | Image: ChemBio
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
